Table 2.
Clinical and Laboratory data for the diabetic subjects during treatment period by Group
| Baseline | 6 | 12 | 18 | 24 | 30 months | |
| BMI (Kg.m-2) | ||||||
| - Group A | 28 (25–31) | 28 (25–32) | 28 (25–32) | 28 (25–32) | 28 (26–32) | 28 (25–32) |
| - Group B | 29 (27–34) | 30 (27–32)& | 30 (27–33)& | 30 (27–32)& | 30 (28–36)& | 30 (27–35)& |
| Waist Circumference(cm) | ||||||
| - Group A | ||||||
| Men | 103 (96–109) | 104 (98–109) | 102 (97–108) | 102 (92–109) | 103 (97–109) | 103 (97–112) |
| Women | 100 (88–114) | 96 (87–113) | 95 (86–110) | 98 (81–113) | 99 (81–114) | 98 (80–115) |
| -Group B | ||||||
| Men | 103 (99–113) | 106 (98–115) | 106 (98–113)& | 103 (99–114) | 103 (98–111) | 104 (95–118) |
| Women | 100 (89–114) | 104 (84–118)& | 110 (83–128)& | 107 (82–125)& | 101 (78–127) | 99 (79–126) |
| SBP mm Hg | ||||||
| - Group A | 140 (135–155) | 137 (130–144) | 135 (125–144)* | 135 (125–145)* | 135 (125–144)* | 130 (125–135)** |
| - Group B | 145 (132–160) | 138 (128–150)* | 135 (127–150)* | 132 (125–144)** | 135 (125–145)** | 135 (121–147)* |
| DBP mm Hg | ||||||
| - Group A | 80 (75–87) | 76 (70–80)* | 75 (70–80)* | 78 (70–80) | 78 (70–80) | 76 (71–80)* |
| - Group B | 85 (76–90) | 79 (70–84) * | 78 (71–80)* | 77 (70–79)* | 77 (69–78)* | 78 (68–79)* |
| HbA1c (%) | ||||||
| - Group A | 7.2 (6.5–8.5) | 7.0 (6.6–7.9) | 7.0 (6.6–7.8) | 6.9 (6.4–7.8) | 7.1 (6.4–7.9) | 7.3 (6.5–7.9) |
| - Group B | 7.5 (6.5–9.2) | 7.3 (6.3–8.2) | 7.4 (6.4–8.0) | 7.0 (6.3–8.2)* | 7.3 (6.4–8.0) | 7.1(6.4–8.3)* |
| ACR (mg/g) | ||||||
| - Group A | 22 (8–145) | 20 (8–99) | 22 (9–66) | 15 (9–76) | 19 (8–86) | 27 (9–97) |
| - Group B | 25 (7–128) | 29 (10–137) | 25 (8–135) | 25 (8–141) | 20 (11–105) | 25 (9–158) |
| Total Cholesterol (mg/dl) | ||||||
| - Group A | 181 (158–208) | 165 (151–182)* | 165 (150–183)* | 155 (135–175)* | 154 (129–166)* | 148 (135–163)** |
| - Group B | 189 (164–217) | 167 (151–200)* | 170 (147–185)* | 159 (141–178)** | 158 (132–182)** | 160 (143–185) ** |
| HDL-Cholesterol (mg/dl) | ||||||
| -Group A | ||||||
| Men | 46 (41–55) | 46 (43–56) | 50 (43–57) | 50 (43–56) | 46 (40–54) | 48 (40–55) |
| Women | 55 (48–65) | 59 (51–71) | 58 (49–65) | 64 (50–66) | 63 (56–68) | 56 (54–64) |
| -Group B | ||||||
| Men | 49 (39–54) | 49 (42–55) | 50 (44–53) | 50 (43–54) | 50 (47–55) | 50 (45–55) |
| Women | 50 (42–60) | 53 (45–64) | 45 (43–58) | 48 (42–58) | 48 (37–55) | 52 (43–57) |
| LDL-Cholesterol (mg/dl) | ||||||
| - Group A | 104 (87–128) | 93 (83–107) | 88 (75–104)* | 77 (66–95)** | 75 (64–94)** | 78 (69–86)** |
| - Group B | 107 (87–136) | 96 (78–112)* | 91 (77–109)* | 82 (72–99)** | 80 (64–98)** | 81 (70–97) ** |
| Triglycerides (mg/dl) | ||||||
| - Group A | 102 (85–145) | 98 (74–149) | 112 (77–139) | 108 (71–138) | 100 (80–141) | 97 (75–137) |
| - Group B | 119 (86–160) | 105 (87–160) | 109 (80–160) | 116 (79–158) | 117 (79–152) | 105 (79–150) |
Group A, diabetic patients treated by endocrinology service. Group B, diabetic patients treated by coordinated team, FP and endocrinologist, at primary care site. Data expressed as median (Q1–Q3).
BMI, body mass index. SBP, Systolic Blood Pressure. DBP, Diastolic Blood Pressure. ACR, albumine-to-creatinine ratio.
*p < 0.05, ** p < 0.01, denote differences in relation to baseline values. &p < 0.05 denote differences between Group A vs. Group B.